SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
JERSEY, Channel Islands, Aug. 30, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chairman and Chief Executive Officer, Paul Cowan, will present at the Morgan Stanley 15th Annual Global Healthcare Conference on Wednesday, September 13, 2017 at 1:35 pm Eastern Time at the Grand Hyatt New York in New York, NY. The Company’s Chief Financial Officer, Chris Lindop, will also be participating in the conference.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Christopher Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
